Loading…
← CockpitCompetitor Analysis › BMRN BioMarin Pharmaceutical Inc.Open in the cockpit ↗

BioMarin Pharmaceutical Inc.BMRNCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Biotech developing treatments for rare genetic diseases, including enzyme replacement therapies and Voxzogo for achondroplasia (dwarfism).

Momentum strong 72
Mkt cap
$11.9B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$136M
20-day average traded
Fwd P/E
11.2×
forward earnings
ROIC−WACC
-0.5 pp
WACC 6.3%
Hurdle
-4 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · USD$61.43
1D+5.0%
1W+5.3%
1M+8.8%
3M-9.2%
6M+22.4%
YTD+3.4%
1Y+12.8%
ATR %3.1%
Beta0.34
52w lowhigh13.4% off high

What BioMarin Pharmaceutical does

Biotech developing treatments for rare genetic diseases, including enzyme replacement therapies and Voxzogo for achondroplasia (dwarfism).

Each product treats a small number of patients at a high price per patient, so a few treatment centers and specialists drive sales, often over many years because the conditions are lifelong. Enzyme therapies for rare metabolic diseases built the base, and Voxzogo, a daily injection for children with achondroplasia, is now the main growth driver.

Products and services

  • Voxzogo (achondroplasia)
  • Enzyme replacement therapies (Vimizim, Naglazyme, Aldurazyme
  • Roctavian (hemophilia gene therapy)

Customers

  • Specialists treating rare genetic/metabolic disord
  • Pediatric endocrinologists (Voxzogo)

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Rare/genetic disease drug discovery and…

What could go right

  • Voxzogo continued volume/international growth
  • Pipeline expansion into additional rare diseases

What could go wrong

  • Small patient populations limit total addressable market
  • Gene therapy (Roctavian) commercial underperformance

Moat: narrow (IP / patents, regulatory licence, installed base). Pioneer and category leader in ultra-rare enzyme-replacement diseases with small, well-identified patient populations.

Headquarters: San Rafael, California, US · Founded: 1997 · Employees: 3,221

Named competitors

BioMarin Pharmaceutical at a glance

Size BioMarin Pharmaceutical (BMRN) is a United States Health Care company (Biotechnology) with a market value of $11.9B, the 695th largest of 3,085 United States companies the cockpit tracks. Shares closed at $61.43 on 18 Nov 2026.

Performance Over six months the shares gained 22.4%, against +23.8% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 19.8% over the last twelve months (peer median +32.0%); the operating margin is 19.2% (peer median 8.5%).

Valuation It trades at 11.2× forward earnings against a peer median of 35.0× (3rd cheapest of 11).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.5 points below its cost of capital (6.3% WACC).

Credit BioMarin Pharmaceutical has 1 bond outstanding ($600M).

Short interest Short interest is 7.3% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012013021 May 202621 Aug 202618 Nov 2026Peer median 124BMRN 114
Six months, rebased to 100: BioMarin Pharmaceutical against the median of its 20 peers (local-currency closes).

BioMarin Pharmaceutical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$3.69B$3.24B$2.84B$2.42B$2.05B
Revenue growth—+14%+17%+18%—
Gross profit$2.63B$2.51B$2.22B$1.84B$1.50B
EBITDA$974M$972M$626M$299M$110M
Net income-$19.1M$349M$427M$168M$142M
Free cash flow$558M$725M$487M$62.6M$54.9M
Capital expenditure$121M$111M$97.4M$108M$132M
Total debt$4.21B$643M$649M$1.13B$1.12B

Quarterly statements and history in the cockpit →

BioMarin Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%1093TECHHALOELANKYMR002422KRYSBBIOPCVX1961701548NBIXSMMTTWSTTXGCGONAXSMIMVTBNTXKODBMRN6-month return →1-month return →
Up and to the right = strong over both horizons. BioMarin Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×100×200×300×1093TECHHALOELAN002422KRYS1961701548NBIXAXSMBMRNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. BioMarin Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%1093TECHHALOELAN002422KRYS1961701548NBIXTXGBMRNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. BioMarin Pharmaceutical is the large dot.

BioMarin Pharmaceutical competitors and peer comparison

Head to head with its named competitors (BMRN vs SAN.PA vs RARE vs ASND)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
BioMarin Pharmaceutical BMRN$11.9B+22%+20%19%11.2×8.2%
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%
Ultragenyx Pharmaceutical RARE$1.81B-24%+16%-64%9.6×n/a
Ascendis Pharma A/S ASND$16.9B+12%+94%18%28.0×19.2%

How BioMarin Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BioMarin Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
MeasureBMRNPeer medianRank in peer set
1-month return+8.8%-5.4%6th highest of 21
6-month return+22.4%+23.8%10th lowest of 21
Distance from 52-week high-13.4%-26.2%5th highest of 21
Revenue growth (TTM)+19.8%+32.0%6th lowest of 17
Operating margin19.2%8.5%7th highest of 17
Forward P/E11.2×35.0×3rd cheapest of 11
Growth the price implies (Req g, 7 yrs)8.2%18.9%5th least demanding of 11
Growth delivered (Del g)+12.0%+18.2%5th lowest of 11
Hurdle (Req g minus delivered)-3.8 pp-3.5 pp6th least demanding of 11
ROIC minus cost of capital-0.5 pp-5.7 pp7th highest of 16
EV / EBITDA15.8×24.0×4th cheapest of 9
Net debt / EBITDA3.6×-1.1×most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%11.2×8.2%+12.0%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%9.1×-10.7%+0.1%
Bio-Techne TECHUnited States$11.4B+56%+1%21%34.4×31.6%+5.5%
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%9.5×-0.3%+39.2%
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%n/an/an/a
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%35.6×6.2%+2.3%
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%36.3×13.1%+26.0%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%42.0×24.6%+38.5%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%294.1×36.9%+19.8%
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%n/an/an/a
10x Genomics TXGUnited States$7.51B+138%-4%-11%n/a47.2%+16.6%
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%n/an/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%77.1×n/an/a
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a

BioMarin Pharmaceutical bonds and credit

BioMarin Pharmaceutical has 1 bond outstanding with $600M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are BioMarin Pharmaceutical's main competitors?
Named competitors: Sanofi (Genzyme) (SAN.PA), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma (ASND). The cockpit's measured peer set (industry) also includes Cspc Pharma (1093.HK), Bio-Techne (TECH), Halozyme Therapeutics (HALO), Elanco Animal Health (ELAN), Kymera Therapeutics (KYMR), Sichuan Kelun Pharmaceutical (002422.SZ).
Is BioMarin Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 11.2× against a peer median of 35.0×, 3rd cheapest of 11 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has BioMarin Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +22.4% against +23.8% for the median peer; over one year +12.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.